15-deoxy-Δ12,14PGJ2 induces diverse biological responses via PPARγ activation in cancer cells

Prostaglandins and Other Lipid Mediators

Volumn 62, Issue 1, 2000, Pages 23-32

  Claya, Carl E ^a   Namen, Andrew M ^a   Fonteh, Alfred N ^a   Atsumi, Genichi ^a,b   High, Kevin P ^b   Chilton, Floyd H ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12 PROSTAGLANDIN J2; CYCLOOXYGENASE 2 INHIBITOR; FIBRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN DERIVATIVE; RETINOID X RECEPTOR; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; WY 16463;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; DOSE RESPONSE; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; NONHUMAN; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 0033886519     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00073-3     Document Type: Article

References (56)

1. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPARγ2 tissue-specific regulator of an adipocyte enhancer . Genes Dev. 8:1994;1224-1234.
2. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156.
3. Satoh T., Furuta K., Suzuki M., Watanabe Y. Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells. Biochem Biophys Res Commun. 258:1999;50-53.
4. Chinery R., Coffey R.J., Graves-Deal R., et al. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res. 59:1999;2739-2746.
5. Saez E., Tontonoz P., Nelson M.C., et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 4:1998;1058-1061.
6. Min/+ mice. Nat Med. 4:1998;1053-1057.
7. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 1995;83:803-12.
8. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A Prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83:1995;813-819.
9. Chwala A., Schwartz E.J., Dinaculangan D.D., Lazar M. Peroxisome proliferator activated receptor (PPAR) γ adipose-predominant expression and induction early in adipocyte differentiation . Endocrinology. 135:1994;798-800.
10. Tontonoz P., Singer S., Forman B.M., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 94:1997;237-241.
11. Altiok S., Xu M., Spiegelman B.M. PPARγ induces cell cycle withdrawal inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A . Genes Dev. 11:1997;1987-1998.
12. Sarraf P., Mueller E., Jones D., et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 4:1998;1046-1052.
13. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1:1998;465-470.
14. Clay C.E., Namen A.M., Atsumi G., et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 20:1999;1905-1911.
15. Elstner E., Muller C., Koshizuka K., et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 95:1998;8806-8811.
16. Chinetti G., Griglio S., Antonucci M., et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 273:1998;25573-25580.
17. Keelan J.A., Sato T.A., Marvin K.W., Lander J., Gilmour R.S., Mitchell M.D. 15-Deoxy-Delta(12,14)-prostaglandin J2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun. 262:1999;579-585.
18. Bishop-Bailey D., Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem. 274:1999;17042-17048.
19. Takahashi N., Okumura T., Motomura W., Fujimoto Y., Kawataba I., Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 455:1999;135-139.
20. Namen AM, High KP, Clay CE, et al. Cell cycle progression, arrest, differentiation, and apoptosis are mediated by the magnitude of PPARγ activation in breast cancer cells (submitted).
21. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:1992;771-774.
22. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA. 90:1993;2160-2164.
23. Gearing K.L., Gottlicher M., Teboul M., Widmark E., Gustafsson J.A. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA. 90:1993;1440-1444.
24. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr Opin Cell Biol. 9:1997;222-232.
25. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain structure and function . Curr Opin Cell Biol. 10:1998;384-391.
26. Gelman L., Fruchart J.C., Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci. 55:1999;932-943.
27. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
28. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384:1996;39-43.
29. Latruffe N., Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie. 79:1997;81-94.
30. Yu K., Bayona W., Kallen C.B., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 270:1995;23975-23983.
31. Schmidt A., Vogel R.L., Witherup K.M., et al. Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family. Lipids. 31:1996;1115-1124.
32. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 94:1997;4312-4317.
33. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 94:1997;4318-4323.
34. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., Lazar M.A. The nuclear eicosanoid receptor, PPARγ is aberrantly expressed in colonic tumors. Carcinogenesis. 19:1998;49-53.
35. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:1998;455-460.
36. Lipsky P.E. The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med. 106:1999;51S-57S.
37. Sasaki H., Fukushima M. Prostaglandins in the treatment of cancer. Anticancer Drugs. 5:1994;131-138.
38. Hirata Y., Hayashi H., Ito S., et al. Occurrence of 9-deoxy-delta 9,delta 12-13,14-dihydroprostaglandin D2 in human urine. J Biol Chem. 263:1988;16619-16625.
39. Shahabi N.A., Chegini N., Wittliff J.L. Alterations of MCF-7 human breast cancer cell after prostaglandins PGA1 and PGF2 alpha treatment. Exp Cell Biol. 55:1987;18-27.
40. Barak Y., Nelson M.C., Ong E.S., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 4:1999;585-595.
41. Kubota N., Terauchi Y., Miki H., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 4:1999;597-609.
42. Rosen E.D., Sarraf P., Troy A.E., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 4:1999;611-617.
43. Lowell B.B. PPARgamma an essential regulator of adipogenesis and modulator of fat cell function . Cell. 99:1999;239-242.
44. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270:1995;12953-12956.
45. Morrison R.F., Farmer S.R. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem. 274:1999;17088-17097.
46. Hansen J.B., Petersen R.K., Larsen B.M., Bartkova J., Alsner J., Kristiansen K. Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinoblastoma protein in adipocyte differentiation. J Biol Chem. 274:1999;2386-2393.
47. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 274:1999;9116-9121.
48. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
49. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
50. Nolte R.T., Wisely G.B., Westin S., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143.
51. Westin S., Kurokawa R., Nolte R.T., et al. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature. 395:1998;199-202.
52. Chakravarti D., LaMorte V.J., Nelson M.C., et al. Role of CBP/P300 in nuclear receptor signalling. Nature. 383:1996;99-103.
53. Gelman L., Zhou G., Fajas L., Raspe E., Fruchart J.C., Auwerx J. p300 Interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively. J Biol Chem. 274:1999;7681-7688.
54. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer 1999;Metastasis Rev 17:401-9.
55. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer 1999;Metastasis Rev 17:401-9.
56. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:1992;879-887.